Investors and Media

Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).

Recent News

Nov 28, 2016Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200Read MoreNov 11, 2016Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 TreatmentRead MoreNov 10, 2016Idera to Present at the Stifel 2016 Healthcare ConferenceRead More

Webcast

November 16, 2016 at 3:00 p.m. ETIdera Pharmaceuticals, Inc. at Stifel 2016 Healthcare Conference
September 26, 2016 at 9:00 a.m. ETIdera Pharmaceuticals, Inc. Corporate Conference Call

Upcoming Events

There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.